Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ:DNTH), a recent reverse merger with the old Magenta Therapeutics.
The analysts initiate with an Outperform rating and a price target of $24.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased